 |
 |
 |
 |
 |
 |
 |
 |
|
IR BioSciences Holdings, Inc. is a development-stage biotechnology company. Through our wholly-owned subsidiary ImmuneRegen BioSciences, Inc., we are engaged in the research and development of the potential drug candidate, Homspera® and its derivatives, Radilex® and Viprovex®. Originally identified as providing protection from radiation exposure, this compound is being evaluated for use as a stimulator of human adult stem cells and as an immune-enhancing agent. Based on these biological activities, Management is focused on development of these drug candidates as potential treatments for blood disorders and to accelerate wound healing. Findings to date suggest additional commercial opportunities as a vaccine adjuvant and potential therapeutic for influenza or other microbial ailments, as well as for use as a possible countermeasure for homeland security threats including radiological, chemical and biological agents.
To learn more about our company, please take a look at our Powerpoint
